Clinical trial · Interventional
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of CNS Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional X-ray examinations, computed tomography (CT) and magnetic resonance imaging (MRI). Changes in the size of the metastases is something that is often seen weeks / months after treatment is completed. At Lund University Hospital, a new imaging technique, diffusional variance decomposition (DIVIDE), has now been developed. With this technique, the scatter in isotropic and anisotropic diffusion can be measured for each measuring point, which provides significantly more information about the properties of the tissue compared to current methods.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Radionecrosis | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
| Sensitivity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brain metastases radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.
- description
- Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.
- interventionNames
- Radiation: Brain metastases radiation
Primary outcomes (12)
- measure
- Grade of radiation sensitivity to brain metastasis.
- timeFrame
- Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3x10 Gy.
- description
- Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
- measure
- Grade of radiation sensitivity to brain metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients prescribed stereotactic radiation therapy to the brain, where MRI imaging is included in the treatment preparations. 2. Cohesive remaining solid tumor component of ≥10mm. 3. Age ≥18 years. 4. World Health Organisation (WHO) performance status 0-1. Exclusion Criteria: 1. Inability to decide for oneself on participation in the study. 2. Inability to understand the Swedish language. 3. Metastases close to the base of the skull. 4. Contraindications to conducting an MRI examination. 5. Contraindications to obtaining contrast media during MRI examination. 6. Expected survival less than 6 months. 7. Previous radiation treatment to the same site in the brain, i.e. current treatment is a rope radiation. \-
References
Publications (0)
Data not yet available